JANX compared with TYRA: revenue, margins and what each company keeps, and the suppliers and customers both name

JANXJanux Therapeutics, Inc.

Mkt capRevenueRevenue

TYRATyra Biosciences, Inc.

Mkt capRevenueRevenue

Compare

JANXJanux Therapeutics, Inc.

TYRATyra Biosciences, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

JANX: latest quarter is a loss; flow not drawable. TYRA: latest quarter not drawable.Method ›

JANXJanux Therapeutics, Inc.

17.48▼−1.96%· post 17.23

Mkt cap$1.1BRevenue$10MQ2 FY26

TYRATyra Biosciences, Inc.

21.08▼−1.86%· post 21.08

ClosedOct 30 '26

Mkt cap$1.3BRevenue—

Compare

ClosedOct 30 '26

JANXJanux Therapeutics, Inc.

TYRATyra Biosciences, Inc.

17.48▼−1.96%post 17.23

Price

21.08▼−1.86%post 21.08

$1.1B

Mkt cap

$1.3B

Q2 FY26$10M

Revenue

—

JANX17.48▼−1.96%vsTYRA21.08▼−1.86%ClosedOct 30 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only JANX 1

MRKMerck Sharp & Dohmecustomer

Shared 0

No disclosed counterparties: TYRA.

Only TYRA 0

None

Role chip = supplier or customerSource: SEC EDGAR

Price

rebased to 0%

JANX, solidTYRA, dashed